Etsy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Etsy Inc trades at $74.75 (market cap $6.90B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.5× Etsy Inc's market cap, and Etsy Inc is more actively traded (2,923,867 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ETSY | VRTX | |
|---|---|---|
Market Cap | $6.90B | $127.55B |
Volume | 2,923,867 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $557.96 |
52-Week Low | $44.05 | $407.37 |
Typical Hold Time | 67 Days | 120 Days |
Enterprise Value | $8.85B | $121.68B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →